# Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma

> **NCT05201326** · PHASE1 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** Bevacizumab，Irinotecan and Re-radiotherapy

## Key facts

- **NCT ID:** NCT05201326
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-22
- **Primary completion:** 2022-12-20
- **Final completion:** 2024-12-20
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05201326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05201326, "Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05201326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*